Avon
This article was originally published in The Rose Sheet
Executive Summary
Third quarter sales were up 4% to $1.9 bil., but were flat in local currency, Avon reports Oct. 28. Net income was down 7% to $163.8 mil., firm adds. U.S. revenues fell 6% to $487.3 mil. due to lower customer purchase frequency and competition, particularly from mass market companies like Procter & Gamble and Johnson & Johnson in the anti-aging skin care category, Avon CEO Andrea Jung says. Beauty sales in the region also were down 6%. U.S. operating profit declined 11% to $63.9 mil. Jung notes she will outline more specific plans to address recent weakness in the company's performance during a Nov. 15 investor meeting...
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.